Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-NK Cells for Paediatric B Cell-related Autoimmune Diseases
NCT07283315Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN5601-K in systemic lupus erythematosus (SLE), nephrotic syndrome, IgA nephropathy (IgAN) and 2 more, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Incidence and severity of dose-limiting toxicity and treatment-emergent adverse events at 1 month, Overall Response Rate at 3 months and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
KN5601-K
03
Conditions
systemic lupus erythematosus (SLE)nephrotic syndromeIgA nephropathy (IgAN)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT07283315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283315.